If we invest heavily in biotechnology and information services companies (especially genomics, networked centralized computing, neurology, neural network predictive applications, and nerve regeneration) in the next 50 years, many currently living people may have an opportunity to achieve substantially improved and lengthened quality of life and indefinitely extended sentience.
It’s more than a financial return, but it can still be evaluated financially. The return on these investments should be calculated as the return on the securities themselves, plus the return on your other investments over the period of time that your life and investment horizon are extended. It is possible, then, that the net return on biotech and information science investments may be substancially higher than the direct value change for those investment securities.
Dan Von Kohorn 